Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing promise in early trials and lab tests. How the new drug works in the ...

Scientists at Lancaster University, University of Southampton, Nottingham Trent University, Tokyo Metropolitan Institute of Medical Science and the University of Texas Southwestern Medical Centre have ...

Scientists have developed a new drug that targets two key regions of the tau protein, a major contributor to Alzheimer’s disease. The drug, a peptide inhibitor called RI-AG03, successfully ...

“RI-AG03 is specifically designed against the Tau protein, meaning it’s less likely to undesirably interact with other proteins,” says Aggidis. While these results, published in the journal ...

RI-AG03 is specifically designed against the Tau protein, meaning it’s less likely to interact with other proteins in an undesirable way.” ...

Brains affected by Alzheimer's disease are characterized by damaging clumps and tangles that interfere with neurons – but a new study describes a drug that could potentially suppress half the problem.

A team of international researchers has found a promising new drug candidate for the treatment of Alzheimer’s disease. The scientists say they have developed a peptide inhibitor called RI-AG03 ...

They found that RI-AG03 penetrated the cells and reduced the aggregation of tau proteins, too. "What is new here, is that the authors have invented a molecule that binds to both tau hotspot regions.

Researchers from a study funded by the Alzheimer’s Society of UK have developed a new drug known as RI-AG03 that they say can prevent the build-up of toxic proteins in the brain that lead to ...

The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized hotspots which are different from tau microtubules. These hotspots, essential ...